Related Experiment Video
Updated: Jul 24, 2025
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.3K
Combinatorial islet protective therapeutic approaches in β-cell transplantation: Rationally designed solutions using
Katie Lu1,2, Timothy Brauns1, Ann E Sluder1
1Vaccine and Immunotherapy Center Massachusetts General Hospital Boston Massachusetts USA.
FASEB Bioadvances
|July 7, 2023
Summary
Islet cell transplantation (ICT) shows promise for type 1 diabetes, but needs a defined target product profile (TPP) and combinatorial approaches to overcome barriers. This strategy can improve long-term islet function and immune protection for wider adoption.
Area of Science:
- Regenerative Medicine
- Immunology
- Endocrinology
Background:
- Islet cell transplantation (ICT) offers a potential alternative to insulin therapy for type 1 diabetes.
- Current ICT approaches have not fully realized their clinical potential, lacking lifelong euglycemia and immune suppression.
- Key challenges include ensuring long-term islet viability, functionality, and localized immune protection.
Purpose of the Study:
- To define a Target Product Profile (TPP) for optimal Islet Cell Transplantation (ICT).
- To explore combinatorial therapeutic strategies to achieve the defined TPP.
- To identify and discuss regulatory barriers hindering ICT adoption.
Main Methods:
- Literature review and synthesis of existing research on ICT.
- Conceptualization and articulation of a novel TPP for ICT.
- Analysis of current and potential combinatorial approaches for ICT.
Main Results:
- A novel TPP for ICT is proposed, emphasizing safety and efficacy.
- Combinatorial strategies are identified as promising for achieving ICT goals.
- Significant regulatory and reimbursement barriers in the US are highlighted.
Conclusions:
- A clearly defined TPP is crucial for advancing ICT.
- Combinatorial approaches are essential for overcoming clinical hurdles in ICT.
- Addressing regulatory and reimbursement issues is vital for widespread ICT adoption in type 1 diabetes treatment.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
437
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
437
01:24Glucagon-like Receptor Agonists
365
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
365